Asymmetric dimethylarginine, endothelial dysfunction and renal disease

Area of Science:

• Biochemistry
• Cardiovascular Science
• Nephrology

Background:

• l-Arginine (Arg) is converted to nitric oxide (NO) by endothelial nitric oxide synthase (NOS).
• Methylation of Arg residues produces methylarginines, like asymmetric dimethylarginine (ADMA), which inhibits NOS.
• Dimethylarginine dimethyaminohydrolase (DDAH) degrades ADMA, regulating NO synthesis.

Purpose of the Study:

• To review the role of ADMA in cardiovascular risk assessment.
• To explore the impact of elevated ADMA levels and reduced DDAH activity on kidney disease and renal transplantation.
• To summarize available data on ADMA levels in renal patients and controls.

Main Methods:

• Literature review of studies on ADMA, NO, DDAH, and kidney disease.
• Analysis of ADMA levels in patients with renal conditions versus healthy controls.
• Examination of the relationship between ADMA, endothelial dysfunction, and renal damage progression.

Main Results:

• Increased ADMA levels are associated with atherosclerotic changes and cardiovascular risk.
• NO production is diminished in renal patients due to elevated ADMA and decreased DDAH activity.
• Elevated ADMA contributes to endothelial dysfunction, oxidative stress, and kidney damage.

Conclusions:

• ADMA is a significant marker for cardiovascular risk and a key factor in the pathophysiology of kidney disease.
• Reduced DDAH activity and subsequent high ADMA levels impair NO synthesis, exacerbating renal damage.
• Therapeutic strategies targeting ADMA reduction may offer benefits for patients with kidney disease.